Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Increased by Ethic Inc.

Key Points

• Ethic Inc. significantly increased its stake in Regeneron Pharmaceuticals by 137.9% in the second quarter, now owning 16,847 shares valued at about $8.8 million.
• A number of institutional investors have also adjusted their positions in Regeneron, with Nuveen LLC acquiring a new position worth approximately $343.8 million during the first quarter.
• Analysts have set varying price targets for Regeneron Pharmaceuticals, with a consensus target price of $817.88 and an overall rating of "Moderate Buy."

Ethic Inc. lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 137.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,847 shares of the biopharmaceutical company's stock after purchasing an additional 9,766 shares during the quarter. Ethic Inc.'s holdings in Regeneron Pharmaceuticals were worth $8,777,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Nuveen LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $343,764,000. Pacer Advisors Inc. raised its position in Regeneron Pharmaceuticals by 2,296.9% during the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after acquiring an additional 390,374 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock valued at $724,984,000 after acquiring an additional 174,056 shares in the last quarter. Vanguard Group Inc. raised its position in Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after acquiring an additional 121,545 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock valued at $1,379,467,000 after acquiring an additional 89,579 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on REGN shares. Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an "overweight" rating on the stock in a research report on Friday, October 10th. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research report on Monday, August 4th. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a report on Monday, August 4th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $817.88.

Regeneron Pharmaceuticals Trading Up 0.9%

Shares of Regeneron Pharmaceuticals stock opened at $584.74 on Thursday. The company's fifty day simple moving average is $576.17 and its 200-day simple moving average is $562.42. The company has a market cap of $61.98 billion, a price-to-earnings ratio of 14.74, a PEG ratio of 1.81 and a beta of 0.31. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $959.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the company posted $11.56 earnings per share. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.